Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M T, Reding"'
Publikováno v:
HemaSphere, Vol 6, Pp 2195-2196 (2022)
Externí odkaz:
https://doaj.org/article/f78de7a253a443a7adaf1559324bed7b
Autor:
Johannes Oldenburg, Karina Meijer, Martin Sanabria, María Teresa Álvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Sabine Friedl, M T Reding
Publikováno v:
BMJ Open, Vol 11, Iss 9 (2021)
Introduction Haemophilia A is a rare bleeding disorder caused by defects in coagulation factor VIII (FVIII). Damoctocog alfa pegol (BAY 94–9027, Jivi, Bayer, Germany) is a site-specifically PEGylated, extended-half-life, recombinant FVIII, approved
Externí odkaz:
https://doaj.org/article/27c7861c02aa44c98351689d40b9cd01
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 18(4)
Acute haemorrhage treatment in patients with congenital haemophilia with inhibitors (CHwI) has transitioned to home. Patient/caregiver perceptions of bleeding symptoms and reasons for starting/stopping treatment were investigated. Frequently bleeding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dc9690ef2789f0f09272a8d260df7fd3
https://pubmed.ncbi.nlm.nih.gov/22348407
https://pubmed.ncbi.nlm.nih.gov/22348407
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 8(1)
Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis. We hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19144fc0006f0827cb036b6c034db677
https://pubmed.ncbi.nlm.nih.gov/11886466
https://pubmed.ncbi.nlm.nih.gov/11886466
Publikováno v:
Advances in experimental medicine and biology. 489
The studies we reviewed here have begun to clarify the complex cellular mechanisms involved in the immune response to fVIII, and the circumstances under which fVIII inhibitors develop. Further characterization and comparison of the immune response to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::50859bc96f7919c6f9bd7f12f7cbebe3
https://pubmed.ncbi.nlm.nih.gov/11554586
https://pubmed.ncbi.nlm.nih.gov/11554586
Autor:
M T, Reding, H, Wu, M, Krampf, D K, Okita, B M, Diethelm-Okita, B A, Christie, N S, Key, B M, Conti-Fine
Publikováno v:
Thrombosis and haemostasis. 84(4)
Antibodies (Ab) that inhibit factor VIII (fVIII) may develop in patients with hemophilia A and rarely in individuals without congenital fVIII deficiency (acquired hemophilia). Synthesis of fVIII inhibitors requires CD4+ T cells. We investigated the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::477729becad6a8bbaa04bcacd948c88e
https://pubmed.ncbi.nlm.nih.gov/11057864
https://pubmed.ncbi.nlm.nih.gov/11057864